Scilex Holding Company · NASDAQ:SCLX
Scilex — SPAC Merger (March 2022)
21 slides from Scilex's SPAC merger presentation, Mar 21, 2022
Slide 1: Innovative Leader in Non-Opioid Pain Therapeutics
Innovative Leader in Non - Opioid Pain Therapeutics (March 2022)
Slide 2: Safe Harbor Statements – Forward-Looking Statements
Safe Harbor Statements Forward - Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be ma de by management of Scilex Holding Company (together with its subsidiaries, “ Scilex ”) orally in presenting this materi
Slide 3: Safe Harbor Statements – Important Information
Safe Harbor Statements Forward - Looking Statements undertakes no obligation to update publicly or revise any forward - looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Scilex’s expectations. Industry and Market D
Slide 4: Safe Harbor Statements – Where to Find It
Safe Harbor Statements Forward - Looking Statements Investors and security holders of the SPAC are urged to read these materials (including any amendments or supplements theret o) and any other relevant documents in connection with the transaction that the SPAC files with the SEC when, and if, they
Slide 5: Safe Harbor Statements – Non-Solicitation
Safe Harbor Statements Forward - Looking Statements Scilex and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the share ho lders of the SPAC in connection with the Proposed Business Combination. Information about Scilex’s directors and
Slide 6: Agenda
Agenda 6 Company Overview / Investment Highlights ZTlido Best - in - Class Profile SP - 102 (SEMDEXA) Potential First - in - Class for Lumbar Radicular Pain / Sciatica – Path to Approval SP - 10 3 ( 3 X ZT li do ) f o r L o w B ac k Pa i n SP - 10 4 DB R Lo w D os e N a ltr exone ( L DN ) f o r F i
Slide 7: Best-in-Class Non-Opioid Pain Therapeutics Platform
Best - in - Class Non - Opioid Pain Therapeutics 7 Platform Program IND P h as e 1 P h as e 2 P h ase3 Pi v o t al NDA Approved U p c om i n g M iles ton es N on - O p i o i d P a i n M a nag e m e n t Z T lid o ® 1.8% (Postherpetic Neuralgia - PHN) Launched US October 2018 SP - 1 0 2 ( SE M D EX A
Slide 8: Scilex Pipeline – Business Opportunity Highlights
Scilex Pipeline – Business Opportunity Highlights 8 ▪ SP - 102 (SEMDEXA - Lumbar Radicular / Sciatica Pain) ▪ Over 12MM ESI procedures performed yearly in US, about 88% are for LRP/sciatica 2 ▪ No product, including currently used ESIs, is approved for epidural use to treat sciatica ▪ Safety warning
Slide 9: Accomplished Executive Team
Accomplished Executive Team 9 Name Position(s) Experience Jaisim Shah CEO & President ▪ 25+ years of management experience in large Pharma and Biotech ▪ Lead commercialization of multiple blockbusters Rituxan ® , Abilify ® , Pegasys ® , Tequin ▪ CEO, Semnur Pharma; CBO, Elevation; CBO, PDL BioPharma
Slide 10: Investment Highlights
Investment Highlights 10 ▪ Scilex Holding Company ( Scilex ), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) signed a merger agreement for the Proposed Business Combination, which provides for a pre - transaction equity value of Scilex of approx
Slide 11: ZTlido – Best in Class Lidocaine Patch - Revenues Continue to Grow at 30%+
ZTlido – Best in Class Lidocaine Patch - Revenues Continue to Grow at 30%+ Annually 11 ▪ Superior non - aqueous transdermal technology allows for better delivery of lidocaine, improved adhesion and thinner patch – weight 2 gms vs 14 gms for Lidoderm and its follow - ons ▪ Supplemental ZTlido sNDA ap
Slide 12: ZTlido YTD Sales Performance Comparison
ZTlido YTD Sales Performance Comparison 12 $63.9MM 2020 2021 ZTlido Gross Sales 2021 vs 2020 $48.3MM + 32 % ∆ $0.0 $10.0 $20.0 $30.0 $40.0 $50.0 $65.0
Slide 13: Epidural Steroid Injections: One of the Most Common Medical Procedures
Epidural Steroid Injections One of the Most Common Medical Procedures and Top Pain Procedure in the U.S. 13 • ESIs w i de l y re i m bur s e d a s p r o c edu r e to de l a y o r a v o i d ba c k s urger y • T ran s fo ra m i n a l ESI r out e (u s e d i n C.L. E.A.R. trial) majority of procedures C
Slide 14: U.S. Market Size — Epidural Steroid Injection (2010-2022)
U.S. Market Size — Epidural Steroid Injection (2010 - 2022) 14
Slide 15: SP-102 (SEMDEXA) – First in Class Treatment - LRP / Sciatica
SP - 102 (SEMDEXA) – First in Class Treatment - LRP / Sciatica 15 Phase 3 SP - 102 C.L.E.A.R Trial – Primary Endpoint Comparison: SP - 102 vs. Placebo Over 4 Weeks, LS Mean (SE) - 1.08 (0.17) 95% CI - 1.42, - 0.75 p - value <0.001*** -3 -2.5 -2 -1.5 -1 -0.5 0 0.5 Week 1 Week 2 Week 3 Week 4 Numeric
Slide 16: C.L.E.A.R. Trial – Key Secondary Endpoint
C.L.E.A.R. Trial – Key Secondary Endpoint The Oswestry Disability Index (ODI) - gold standard for measuring degree of disability and estimating quality of life. Highly statistically significant result for SEMDEXA over placebo. ODI contains 10 topics concerning intensity of pain, lifting, ability to
Slide 17: Phase 3 SP-102 C.L.E.A.R. Trial - Conclusions
Phase 3 SP - 102 C.L.E.A.R. Trial - Conclusions 17 ▪ The trial met primar y, key secondary and other secondary endpoint s with high statistical significance over placebo ▪ Achieved all study objectives supporting first - in - class efficacy and safety results ▪ Demonstrated clear safety profile of S
Slide 18: SEMDEXA – Broad Potential for Life Cycle Management
SEMDEXA – Broad Potential for Life Cycle Management 18 Physicians indicated there is potential opportunity for spontaneous use of SEMDEXA outside of lumbar radiculopathy which could represent an additional upside of ~50 - 200%* over LR Additional Potential Uses ▪ Carpe l T unnel ▪ Trigger Point Inje
Slide 19: SP-103 is a Next-Generation, Triple Strength Formulation of ZTlido 1.8%
SP - 103 is a Next - Generation, Triple Strength Formulation of ZTlido 1.8% Tartgeting the Low Back Pain Opportunity 19 x 3 x d r ug lo a d ( 10 8 m g vs 3 6 m g lido c ai n e) x T r ipl e s t r e ngth lo ca l i z e d do s e of lidocaine x E x pe c t e d s a m e s up e r ior a dh es ion a nd efficie
Slide 20: Summary of Post Business Combination Plans
Summary of Post Business Combination Plans 20 Clinical development and CMC activities ▪ M anufacture of clinical supplies for SP - 103 and SP - 104 , commercial manufacturing for SP - 102 ▪ Advance SP - 103 and SP - 104 in U.S. Phase 2/3 clinical trials ▪ Pursue ex - U.S. development for our pipelin
Slide 21: Scilex Holding Company Summary
Scilex Holding Company Summary 21 Commercial non - opioid pain management company with 3 clinical non - opioid programs in la rg e mar k e t s with v er y h i g h un m e t nee d Launched rapidly growing ZTlido (lidocaine topical system 1.8%) in 2018 with in - house commercial and sales team Semnur P